|
Myelodysplastic Syndromes and Iron Chelation Therapy
|
Mar 2017
|
Mediterr J Hematol Infect Dis
|
myelodysplastic syndromes (MDS)
|
|
Diagnostic Utility of Flow Cytometry in Myelodysplastic Syndromes.
|
Feb 2017
|
Mediterr J Hematol Infect Dis
|
myelodysplastic syndromes (MDS)
|
|
Inflammatory arthritis in patients with myelodysplastic syndromes: a multicenter retrospective study and literature review of 68 cases
|
Jan 2014
|
Medicine (Baltimore)
|
|
|
Effect of erythropoiesis-stimulating agent policy decisions on off-label use in myelodysplastic syndromes
|
Nov 2014
|
Medicare Medicaid Res Rev
|
myelodysplastic syndromes (MDS)
|
|
Primary Myelodysplastic Syndromes: The Mayo Clinic Experience With 1000 Patients
|
Nov 2015
|
Mayo Clin Proc
|
myelodysplastic syndromes (MDS)
|
|
Polymorphisms of Interlukin-1β rs16944 confer susceptibility to myelodysplastic syndromes
|
Nov 2016
|
Life Sci.
|
myelodysplastic syndromes (MDS)
|
|
Rewriting the rules for care of MDS and AML patients in the time of COVID-19
|
Apr 2020
|
Leukemia Research Reports
|
acute myeloid leukemia (AML), myelodysplastic syndromes (MDS)
|
|
Patient and physician perceptions about blood transfusions in the myelodysplastic syndromes
|
Jul 2020
|
Leukemia Research
|
myelodysplastic syndromes (MDS)
|
|
A phase 2 trial of the oral smoothened inhibitor glasdegib in refractory myelodysplastic syndromes (MDS)
|
Mar 2019
|
Leukemia Research
|
myelodysplastic syndromes (MDS)
|
|
Outcome of lower-risk myelodysplastic syndrome with ring sideroblasts (MDS-RS) after failure of erythropoiesis- stimulating agents
|
Dec 2020
|
Leukemia Research
|
myelodysplastic syndromes (MDS)
|
